Literature DB >> 10639371

Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.

A H Groll1, D Mickiene, S C Piscitelli, T J Walsh.   

Abstract

The distribution of the three currently available lipid formulations of amphotericin B (AmB) into bone marrow and fat tissue was evaluated in noninfected rabbits. Groups of four animals each received either 1 mg of AmB deoxycholate (D-AmB) per kg of body weight per day or 5 mg of AmB colloidal dispersion, AmB lipid complex, or liposomal AmB per kg per day for seven doses. Plasma, bone marrow, fat, and liver were collected at autopsy, and AmB concentrations were determined by high-performance liquid chromatography. At the investigated dosages of 5 mg/kg/day, all AmB lipid formulations achieved at least fourfold-higher concentrations in bone marrow than did standard D-AmB at a dosage of 1 mg/kg/day. Concentrations in bone marrow were 62 to 76% of concurrent AmB concentrations in the liver. In contrast, all AmB formulations accumulated comparatively poorly in fat tissue. The results of this study show that high concentrations of AmB can be achieved in the bone marrow after administration of lipid formulations, suggesting their particular usefulness against disseminated fungal infections involving the bone marrow and against visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639371      PMCID: PMC89692          DOI: 10.1128/AAC.44.2.408-410.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

Authors:  A H Groll; S C Piscitelli; T J Walsh
Journal:  Adv Pharmacol       Date:  1998

Review 2.  Lipid formulations of amphotericin B: recent progress and future directions.

Authors:  J W Hiemenz; T J Walsh
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

Review 3.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.

Authors:  J D Berman
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

Review 4.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

5.  A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects.

Authors:  S N Schwartz; G J Pazin; J A Lyon; M Ho; A W Pasculle
Journal:  J Infect Dis       Date:  1978-10       Impact factor: 5.226

Review 6.  Histoplasmosis in the acquired immunodeficiency syndrome.

Authors:  J Wheat
Journal:  Curr Top Med Mycol       Date:  1996-12

7.  Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.

Authors:  A B Mullen; K C Carter; A J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

8.  Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.

Authors:  J W Lee; M A Amantea; P A Francis; E E Navarro; J Bacher; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 9.  Practical guide for the treatment of leishmaniasis.

Authors:  R N Davidson
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents.

Authors:  R T Proffitt; A Satorius; S M Chiang; L Sullivan; J P Adler-Moore
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

View more
  9 in total

1.  Amphotericin B-impregnated bone cement to treat refractory coccidioidal osteomyelitis.

Authors:  Elizabeth S Zhu; George R Thompson; Christopher Kreulen; Eric Giza
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

2.  Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis.

Authors:  A Garcia; J P Adler-Moore; R T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 3.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011).

Authors:  Maria N Gamaletsou; Dimitrios P Kontoyiannis; Nikolaos V Sipsas; Brad Moriyama; Elizabeth Alexander; Emmanuel Roilides; Barry Brause; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-08-21       Impact factor: 9.079

Review 5.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

Review 6.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

Review 7.  Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications.

Authors:  Tammy Haro-Reyes; Lucero Díaz-Peralta; Arturo Galván-Hernández; Anahi Rodríguez-López; Lourdes Rodríguez-Fragoso; Iván Ortega-Blake
Journal:  Membranes (Basel)       Date:  2022-06-30

Review 8.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08

Review 9.  Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review.

Authors:  Beatrijs Mertens; Ruth Van Daele; Melissa Depypere; Katrien Lagrou; Yves Debaveye; Joost Wauters; Stefaan Nijs; Willem-Jan Metsemakers; Isabel Spriet
Journal:  Antibiotics (Basel)       Date:  2022-03-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.